77 patents
Page 3 of 4
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
4 Jan 21
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Elazar Rabbani, James J. Donegan
Filed: 7 Apr 20
Utility
Fluorescent dyes and methods of use thereof
28 Dec 20
Zaiguo Li, Praveen Pande
Filed: 10 Sep 18
Utility
Monoazo dyes with cyclic amine as fluorescence quenchers
14 Dec 20
The present disclosure provides reactive quencher dyes that can be used in the detection and/or quantification of desirable target molecules, such as proteins, nucleic acids and various cellular organelles.
Zaiguo Li, Praveen Pande, Natarajan Raju
Filed: 5 Oct 18
Utility
Immunomodulatory Pharmaceutical Compositions
25 Nov 20
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
Filed: 1 Jun 20
Utility
Digallic Acid for Reduction of Inflammatory Cytokine Activity
18 Nov 20
The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors.
Elazar Rabbani, Xiaofeng Li, Dakai Liu, Yazhou Zhang, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, James J. Donegan
Filed: 20 Apr 20
Utility
Methods for Treating Psoriasis
21 Oct 20
The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.
YARON ILAN, ERAN ELINAV
Filed: 1 Jul 20
Utility
Nucleic Acid Probes for In Situ Hybridization
21 Oct 20
a The invention provides nucleic acid hybridization probes having improved detectability that include a plurality of first segments consecutively complementary to a target nucleic acid sequence and, between neighboring first segments, a nucleic acid spacer segment which is not complementary to the target nucleic acid sequence and which may include labeled nucleic acid residues.
ELAZAR RABBANI, JAMES J. DONEGAN, JACK COLEMAN, MAURIZIO MAURO
Filed: 5 Jul 20
Utility
Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor
14 Oct 20
Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin.
Joshua RABBANI
Filed: 25 Mar 20
Utility
Self-immolative Probes for Enzyme Activity Detection
16 Sep 20
Irina LEBEDEVA, Wayne Forest PATTON, Maciej SZCZEPANIK, Yuejun XIANG, Praveen PANDE
Filed: 27 May 20
Utility
Glucocerebroside Treatment of Disease
9 Sep 20
The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects.
Yaron ILAN, Maya MARGALIT, Ari ZIMRAN
Filed: 25 Feb 20
Utility
Compounds and Methods for Detection of Enzymes That Remove Methyl Succinyl Groups from Epsilon-amino Lysine Moieties
9 Sep 20
Konrad T. Horwitz, Zhongda Zhang, Anne Kisielewski, Elizabeth Dale, Wayne Forrest Patton
Filed: 29 Mar 20
Utility
Methods for treating psoriasis
27 Jul 20
The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.
Yaron Ilan, Eran Elinav
Filed: 2 Jun 19
Utility
Sphingosine Pathway Modulating Compounds for the Treatment of Cancers
22 Jul 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Elazar Rabbani, James J. Donegan
Filed: 7 Apr 20
Utility
Self-immolative probes for enzyme activity detection
20 Jul 20
Irina Lebedeva, Wayne Forrest Patton, Maciej Szczepanik, Yuejun Xiang, Praveen Pande
Filed: 31 Oct 18
Utility
Sphingosine Pathway Modulating Compounds for the Treatment of Cancers
15 Jul 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Elazar Rabbani, James J. Donegan
Filed: 25 Mar 20
Utility
Immunomodulatory pharmaceutical compositions
13 Jul 20
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan
Filed: 12 Jun 19
Utility
Sphingosine Kinase Type 1 Inhibitors and Uses Thereof
24 Jun 20
Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management.
Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
Filed: 9 Mar 20
Utility
Methods and intermediates for synthesizing SK1-I
15 Jun 20
The invention provides methods for synthesizing the compound (2R,3S,4E)-N-methyl-5-(4′-pentylphenyl)-2-aminopent-4-ene-1,3-diol, also known as SK1-I, and intermediate compounds used in its synthesis.
Zaiguo Li, Natarajan Raju, Praveen Pande
Filed: 12 May 19
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
8 Jun 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Elazar Rabbani, James J. Donegan
Filed: 24 Jun 18
Utility
Sphingosine pathway modulating compounds for the treatment of cancers
25 May 20
The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
Elazar Rabbani, James J. Donegan, Paul Diamond
Filed: 20 Dec 18